Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 10.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,477 shares of the biopharmaceutical company’s stock after purchasing an additional 143 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Loxo Oncology were worth $207,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Dorsey Wright & Associates boosted its stake in Loxo Oncology by 20.0% during the fourth quarter. Dorsey Wright & Associates now owns 312 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 52 shares during the period. Strs Ohio grew its stake in shares of Loxo Oncology by 0.9% during the fourth quarter. Strs Ohio now owns 10,900 shares of the biopharmaceutical company’s stock worth $1,526,000 after acquiring an additional 100 shares during the last quarter. Cornerstone Advisors Inc. grew its stake in shares of Loxo Oncology by 46.0% during the fourth quarter. Cornerstone Advisors Inc. now owns 387 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 122 shares during the last quarter. Meeder Asset Management Inc. boosted its position in Loxo Oncology by 177.0% in the fourth quarter. Meeder Asset Management Inc. now owns 338 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 216 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in Loxo Oncology by 26.7% in the fourth quarter. IFP Advisors Inc now owns 1,180 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 249 shares during the last quarter. Institutional investors and hedge funds own 96.42% of the company’s stock.
Several equities research analysts have commented on the company. William Blair restated a “buy” rating on shares of Loxo Oncology in a research report on Tuesday, November 27th. Cowen reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Monday, October 22nd. Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a report on Saturday, November 10th. Citigroup increased their price target on Loxo Oncology to $201.00 and gave the stock a “buy” rating in a report on Wednesday, November 28th. Finally, Oppenheimer assumed coverage on Loxo Oncology in a report on Friday, December 21st. They set a “buy” rating and a $185.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $193.46.
LOXO traded up $0.02 on Wednesday, reaching $234.73. The company’s stock had a trading volume of 3,718 shares, compared to its average volume of 1,715,802. The company has a market capitalization of $7.19 billion, a P/E ratio of -44.21 and a beta of 2.51. Loxo Oncology Inc has a 1 year low of $92.32 and a 1 year high of $234.78.
TRADEMARK VIOLATION WARNING: “Loxo Oncology Inc (LOXO) Position Raised by Zurcher Kantonalbank Zurich Cantonalbank” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2019/02/13/loxo-oncology-inc-loxo-position-raised-by-zurcher-kantonalbank-zurich-cantonalbank.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Further Reading: What are municipal bonds?
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.